Perioperative atezolizumab plus chemotherapy more than doubles event-free survival in resectable stage II–IIIB NSCLC
Source Summary
Final results from the Phase III IMpower030 trial show that patients with resectable stage II–IIIB non-small cell lung cancer treated with perioperative atezolizumab plus platinum-based chemotherapy achieved a median event-free survival of 62.8 months, compared with 34.9 months for those receiving chemotherapy alone. This represents more than a doubling of event-free survival with the addition of atezolizumab to standard chemotherapy.
Why it matters
This trial demonstrates that adding atezolizumab to perioperative chemotherapy significantly improves survival outcomes in patients with resectable stage II–IIIB NSCLC, potentially establishing a new treatment standard for this patient population.
